charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro
Company profile
Ticker
CRL
Exchange
Website
CEO
James Foster
Employees
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Syneos Health • Icon • Medpace • Incyte • Zymergen • OmniAb • SomaLogic ...
Former names
CHARLES RIVER LABORATORIES HOLDINGS INC, CHARLES RIVER LABORATORIES INTERNATIONAL INC
SEC CIK
Corporate docs
Subsidiaries
Charles River Laboratories, Inc. • Charles River UK Limited • Charles River Laboratories Saint‑Constant S.A. • Charles River Nederland B.V. • Charles River Laboratories Holding SAS • Charles River Laboratories France C.R.L.F. SAS • BioFocus DPI (Holdings) Ltd. • Charles River Laboratories Belgium SRL • Charles River Laboratories España SA • Charles River Laboratories Italia Srl ...
IRS number
61397316
CRL stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
24 Apr 24
ARS
2023 FY
Annual report to shareholders
29 Mar 24
DEF 14A
Definitive proxy
29 Mar 24
10-K
2023 FY
Annual report
14 Feb 24
8-K
Results of Operations and Financial Condition
14 Feb 24
8-K
Departure of Directors or Certain Officers
24 Jan 24
8-K
Departure of Directors or Certain Officers
16 Jan 24
UPLOAD
Letter from SEC
5 Dec 23
CORRESP
Correspondence with SEC
21 Nov 23
8-K
Other Events
15 Nov 23
Transcripts
CRL
Earnings call transcript
2023 Q4
14 Feb 24
CRL
Earnings call transcript
2023 Q3
8 Nov 23
CRL
Earnings call transcript
2023 Q2
9 Aug 23
CRL
Earnings call transcript
2023 Q1
11 May 23
CRL
Earnings call transcript
2022 Q4
22 Feb 23
CRL
Earnings call transcript
2022 Q3
2 Nov 22
CRL
Earnings call transcript
2022 Q2
3 Aug 22
CRL
Earnings call transcript
2022 Q1
4 May 22
CRL
Earnings call transcript
2021 Q4
17 Feb 22
CRL
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4/A
Victoria L Creamer
25 Mar 24
4/A
JAMES C FOSTER
25 Mar 24
4/A
Shannon M Parisotto
25 Mar 24
4/A
William D Barbo
25 Mar 24
4/A
Joseph W LaPlume
25 Mar 24
4/A
Birgit Girshick
25 Mar 24
4/A
Michael Gunnar Knell
25 Mar 24
4
Michael Gunnar Knell
11 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
Michael Gunnar Knell
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jul 23 | Apr 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 165.62 mm | 165.62 mm | 165.62 mm | 165.62 mm | 165.62 mm | 165.62 mm |
Cash burn (monthly) | 14.39 mm | 2.55 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 99.04 mm | 17.53 mm | n/a | n/a | n/a | n/a |
Cash remaining | 66.58 mm | 148.08 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 4.6 | 58.1 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
99.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 614 |
Opened positions | 83 |
Closed positions | 67 |
Increased positions | 226 |
Reduced positions | 208 |
13F shares | Current |
---|---|
Total value | 10.00 tn |
Total shares | 51.14 mm |
Total puts | 282.80 k |
Total calls | 187.10 k |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 5.95 mm | $1.17 tn |
BLK Blackrock | 5.12 mm | $1.00 tn |
STT State Street | 2.03 mm | $397.02 bn |
Kayne Anderson Rudnick Investment Management | 1.75 mm | $342.20 bn |
Clearbridge Advisors | 1.75 mm | $342.18 bn |
T. Rowe Price | 1.68 mm | $331.12 bn |
Allspring Global Investments | 1.20 mm | $234.24 bn |
Geode Capital Management | 1.12 mm | $219.58 bn |
Ariel Investments | 1.07 mm | $209.03 bn |
IVZ Invesco | 927.90 k | $181.85 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Mar 24 | Knell Michael Gunnar | Common Stock | Sell | Dispose S | No | No | 267.52 | 808 | 216.16 k | 7,024 |
4 Mar 24 | Knell Michael Gunnar | Common Stock | Sell | Dispose S | No | No | 261.35 | 1,000 | 261.35 k | 7,832 |
4 Mar 24 | Knell Michael Gunnar | Common Stock | Sell | Dispose S | No | No | 260.88 | 1,750 | 456.54 k | 8,832 |
1 Mar 24 | Shannon M Parisotto | Common Stock | Gift | Dispose G | Yes | No | 0 | 412 | 0.00 | 26,554 |
29 Feb 24 | Victoria L Creamer | Common Stock | Sell | Dispose S | No | No | 253.7 | 5,000 | 1.27 mm | 13,550 |
29 Feb 24 | Shannon M Parisotto | Common Stock | Sell | Dispose S | No | No | 254.02 | 100 | 25.40 k | 7,132 |
29 Feb 24 | Shannon M Parisotto | Common Stock | Sell | Dispose S | No | No | 253.43 | 3,686 | 934.14 k | 4,792 |
15 Feb 24 | Girshick Birgit | Common Stock | Gift | Dispose G | No | No | 0 | 424 | 0.00 | 47,691 |
News
FibroBiologics, Charles River Laboratories Sign Letter Of Intent Allowing For Transfer, Testing And Validation Of Technology
25 Apr 24
Charles River To Perform Plasmid Production For Ship Of Theseus
4 Apr 24
Evaluating Charles River: Insights From 7 Financial Analysts
18 Mar 24
Argus Research Maintains Buy on Charles River, Raises Price Target to $290
18 Mar 24
Charles River And Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
14 Mar 24
Press releases
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties
23 Apr 24
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
12 Apr 24
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
11 Apr 24
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
2 Apr 24
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
27 Mar 24